12 岁的肯德里克·克罗默 (Kendric Cromer) 使用 Lyfgenia 接受了首次商业许可的镰状细胞病基因治疗。 12-year-old Kendric Cromer receives first commercially licensed gene therapy for sickle cell disease using Lyfgenia.
来自华盛顿的 12 岁男孩肯德里克·克罗默成为全球首位接受商业许可的镰状细胞病基因治疗的人，这对美国 20,000 名镰状细胞病患者来说是一个重要的里程碑。 12-year-old Kendric Cromer from Washington has become the first person worldwide to receive commercially licensed gene therapy for sickle cell disease, marking a significant milestone for the 20,000 US patients who suffer from the condition. 这种名为 Lyfgenia 的治疗方法由 Bluebird Bio 公司开发，并于 12 月获得 FDA 批准。 The treatment, called Lyfgenia, was developed by Bluebird Bio and approved by the FDA in December. 它为符合条件的人带来了希望，但也凸显了患者在获得新的镰状细胞治疗方法方面所面临的挑战。 It offers hope to those who qualify, but also highlights the challenges patients face in accessing new sickle cell treatments.